MedTrace Logo

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

NCT00482079 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 743

Last updated 2017-03-28

No results posted yet for this study

Summary

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

Conditions

  • Diabetes Mellitus, Type II

Interventions

DRUG

MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-13
Primary Completion
2004-08-25
Completion
2006-06-15

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00482079 on ClinicalTrials.gov